Hyperfine Q2 Revenue Climbs 45% to $3.9M, Full-Year Guidance of $20–$22M Reaffirmed

summarizeSummary

Hyperfine reported Q2 2026 revenue of $3.9 million, up 45% year-over-year, with improved gross margins and reaffirmed full-year guidance. Key regulatory milestones in Europe and record U.S. scan volumes were achieved, while the company maintained a strong cash position of $43.5 million.

check_boxKey Events · Earnings and Guidance · HYPR

• Q2 Revenue Growth of 45%

  Revenue reached $3.9 million, up from $2.7 million in Q2 2025, driven by 12 Swoop system sales (50% increase).

• Gross Margin Expansion

  Gross profit of $2.0 million represented a 50.7% margin, up from 49.3% a year ago, reflecting improved product economics.

• Full-Year Guidance Reaffirmed

  Management reiterated 2026 revenue guidance of $20–$22 million (55% growth at midpoint) and cash burn of $26–$28 million.

• European Regulatory Milestones

  Obtained CE Mark and UKCA approval for the next-generation Swoop system and Optive AI software, enabling European commercial launch with initial sales.

auto_awesomeAnalysis · HYPR · Industrial Applications And Services

Driven by a 50% jump in Swoop system placements, Hyperfine posted 45% year-over-year revenue growth to $3.9 million in Q2 2026. Gross margins expanded to 50.7% while operating expenses declined, narrowing the net loss to $9.3 million. The company reaffirmed its full-year revenue outlook of $20–$22 million and cash burn of $26–$28 million, supported by a $43.5 million cash position that extends its runway. The quarter also delivered CE Mark and UKCA approvals, paving the way for a European commercial launch, alongside record U.S. scan volumes that signal growing clinical adoption. The $0.6 million non-cash warrant liability fair value loss is a mark-to-market adjustment tied to share price movement, not a cash outflow or new dilution.